www.accesswire.com
Open in
urlscan Pro
2606:4700:20::ac43:4322
Public Scan
URL:
https://www.accesswire.com/917238/stockholders-can-assist-the-schall-law-firm-in-a-securities-fraud-lawsuit-against-cvs-hea...
Submission: On September 18 via manual from US — Scanned from DE
Submission: On September 18 via manual from US — Scanned from DE
Form analysis
0 forms found in the DOMText Content
Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting * ABOUT * WHO WE ARE * WHO WE SERVE * CONTACT * PRODUCTS * PRESS RELEASE DISTRIBUTION * PRESS RELEASE OPTIMIZER * MEDIA SUITE * MEDIA DATABASE * MEDIA PITCHING * MEDIA MONITORING * MEDIA ROOM * IR WEBSITES * WEBCASTING * NEWSROOM * RESOURCES * LIBRARY * BLOG * COMPANY SPOTLIGHT * PRESS RELEASE SAMPLE * PRESS RELEASE TEMPLATE * FAQ * CUSTOMER REVIEWS * LOGIN SUBMIT A PRESS RELEASE -------------------------------------------------------------------------------- Back to Newsroom STOCKHOLDERS CAN ASSIST THE SCHALL LAW FIRM IN A SECURITIES FRAUD LAWSUIT AGAINST CVS HEALTH CORPORATION Friday, 13 September 2024 11:00 AM The Schall Law Firm Visit Newsroom Share this Article Topic: Class Action LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. CVS failed to properly forecast medical cost trends and health care utilization rates. The Company was forced to incur material costs due to its ineffective forecasts. The Company overstated the profitability of its Health Care Benefits division. Despite its assurances, the Company's profits from other business segments were not sufficient to cover the increasing expenses incurred by the Health Care Benefits segment. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about CVS, investors suffered damages. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq. www.schallfirm.com Office: 310-301-3335 info@schallfirm.com SOURCE: The Schall Law Firm Topic: Class Action Back to Newsroom CONTACT US TODAY IF YOU HAVE QUESTIONS OR WANT TO LEARN MORE ABOUT OUR PRODUCTS, OUR TEAM’S HERE TO HELP! Contact Us -------------------------------------------------------------------------------- ABOUT WHO WE ARE WHO WE SERVE CONTACT PRODUCTS PRESS RELEASE DISTRIBUTION PRESS RELEASE OPTIMIZER MEDIA SUITE MEDIA DATABASE MEDIA PITCHING MEDIA MONITORING MEDIA ROOM IR WEBSITES WEBCASTING NEWSROOM RESOURCES LIBRARY FAQ COMPANY SPOTLIGHT PRESS RELEASE SAMPLE PRESS RELEASE TEMPLATE BLOG CUSTOMER REVIEWS LOGIN CONNECT TODAY! SALES EDITORIAL CONTENT LICENSING JOIN OUR NEWSLETTER 866-694-3099 -------------------------------------------------------------------------------- © 2024 ACCESSWIRE | All Rights Reserved * PRIVACY POLICY * TERMS OF SERVICE * RESPONSIBLE DISCLOSURE GUIDELINES * Status Share by: